A measles-derived peptide treats and vaccinates against adjuvant arthritis

Area of Science:

• Immunology
• Rheumatology
• Virology

Background:

• Adjuvant arthritis (AA) is an autoimmune disease model.
• Measles infection has been anecdotally linked to rheumatoid arthritis remission.
• Myelin basic protein (MBP) is involved in autoimmune responses.

Purpose of the Study:

• To investigate the therapeutic potential of measles vaccine and porcine MBP in adjuvant arthritis.
• To explore the anti-arthritic activity of peptides derived from homologous regions between measles virus proteins and MBP.

Main Methods:

• Lewis rats were induced with adjuvant arthritis.
• Treatment with measles vaccine or porcine MBP was administered before or after arthritis onset.
• Synthesized peptides based on measles virus-MBP homology were tested for efficacy.
• Preventive and therapeutic effects on AA were evaluated.

Main Results:

• Both measles vaccine and porcine MBP significantly ameliorated or abolished AA symptoms.
• A specific 20-amino acid peptide demonstrated significant anti-arthritic activity.
• Pre-inoculation with the peptide prevented the onset of AA.
• The peptide was effective in both preventing arthritis and treating pre-existing conditions.

Conclusions:

• Measles vaccine and MBP show therapeutic potential for autoimmune arthritis.
• Identified peptides from measles virus-MBP homology possess significant anti-arthritic properties.
• These findings suggest the development of novel therapeutic vaccines for certain types of arthritis.